RestructuringApr 29, 2026, 04:07 PM
AUTL Cuts 13% Workforce; Targets $15M Annual Savings; Reaffirms 2026 Revenue
AI Summary
Autolus Therapeutics plc announced a strategic initiative to improve operational efficiency and reduce operating expenses, including a workforce reduction of approximately 13%. This is expected to result in $15 million in annualized operating expense reductions starting in 2027 and $8 million in restructuring charges. The company reiterated its full-year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million, up from $74 million in 2025, and anticipates a shift to positive gross margin in 2026. Clinical development programs remain on track, and the company expects its cash runway to extend into the fourth quarter of 2027.
Key Highlights
- AUTL to reduce headcount by approximately 13%
- Expected to reduce operating expenses by approximately $15 million annually starting 2027
- Anticipates incurring total restructuring charges of approximately $8 million, mostly in H1 2026
- Reiterates full year 2026 AUCATZYL net product revenue guidance of $120 million to $135 million
- 2025 AUCATZYL net product revenue was $74 million
- Anticipates a shift to positive gross margin in 2026
- Current cash runway expected to fund operations into Q4 2027